MedTrace Logo

Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy

NCT02864615 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-10-22

No results posted yet for this study

Summary

Aim of this phase 1b study is to evaluate safety and preliminary efficacy of stereotactic body radiation therapy in patients with metastatic renal cell carcinoma treated with VEGFR, mTOR or immune checkpoint inhibitors.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

RADIATION

SBRT

Dose and schedule will be depended on metastases location.

Sponsors & Collaborators

  • Kidney Cancer Research Bureau

    lead OTHER

Principal Investigators

  • Ilya Tsimafeyeu, M.D. · Kidney Cancer Research Bureau

  • Natalia Dengina, M.D. · Ulyanovsk Regional Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-01-31
Completion
2018-08-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02864615 on ClinicalTrials.gov